Maxolon (Metoclopramide Hydrochloride)

Maxolon (metoclopramide) acts on dopaminergic and serotonergic pathways to manage several gastrointestinal and emetic conditions.

• Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone.
• Gastroparesis: accelerates gastric emptying and improves related symptoms.
• Gastro‑oesophageal reflux disease (GERD): decreases reflux episodes by enhancing lower esophageal sphincter tone.

• Metoclopramide antagonizes dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the central stimulus for nausea and vomiting. Simultaneously it stimulates serotonin 5‑HT4 receptors in the gastrointestinal tract, promoting acetylcholine release and enhancing coordinated smooth‑muscle contractions, which accelerates gastric emptying and improves lower esophageal sphincter tone. The combined dopaminergic blockade and serotonergic agonism produce both antiemetic and pro‑kinetic effects, making the drug useful in disorders where delayed gastric motility contributes to symptoms.

Metoclopramide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness: feeling of sleepiness or reduced alertness.
• Fatigue: general lack of energy.
• Restlessness: inner sense of agitation or inability to stay still.
• Diarrhea: loose, frequent stools.
• Headache: mild to moderate head pain.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Tardive dyskinesia: involuntary, repetitive movements, potentially irreversible.
• Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
• Severe depression or suicidal thoughts: marked mood changes requiring immediate attention.
• Seizures: convulsive episodes.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms.

When prescribing metoclopramide, clinicians should consider several safety precautions to minimize risk.

• Renal impairment: adjust dose or monitor closely in patients with reduced kidney function.
• Hypersensitivity: discontinue if allergic reactions such as rash or swelling occur.
• Extrapyramidal symptoms: observe for muscle rigidity, tremor, or abnormal movements, especially in high‑risk patients.
• Elderly patients: use the lowest effective dose and limit duration to reduce adverse effects.
• Concomitant dopamine antagonists: avoid combining with other drugs that block dopamine receptors.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Metoclopramide can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol): additive dopamine blockade may worsen extrapyramidal effects.
• Monoamine oxidase inhibitors (MAOIs): combined use can increase risk of hypertensive crisis and serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Opioids (e.g., morphine): may enhance central nervous system depression.
• Anticholinergic drugs: may reduce the pro‑kinetic effect of metoclopramide.
• Antihistamines (e.g., diphenhydramine): can increase sedation.
• Alcohol: may potentiate drowsiness and dizziness.